Wearable AI diagnostics company Seers said on the 29th that its wearable electrocardiogram (ECG) monitor, mobiCARE™, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).
The clearance is significant not only because it completes the regulatory process for U.S. commercialization, but also because it moves up the company’s U.S. business roadmap ahead of schedule. Seers had expected to receive FDA 510(k) clearance in the third quarter after submitting its final application in May, but secured clearance by the end of June, allowing it to establish an earlier foothold in the U.S. market.
The approval also enables Seers to accelerate its planned Medical Concierge-based ECG testing service in the United States. The company has been pursuing a strategy of conducting outpatient proof-of-concept (PoC) studies with local healthcare providers before entering the Medicare reimbursement market. With FDA clearance obtained earlier than expected, the outpatient validation schedule can also move forward, while future Medicare reimbursement and commercialization are expected to proceed as planned.
The United States is one of the world’s largest markets for arrhythmia diagnosis, with more than 14 million diagnostic tests performed annually. Medicare reimbursement for ECG testing is approximately $250 per test, making it a significantly higher-value market than Korea. Demand for long-term wearable ECG monitoring is also growing rapidly as populations age and cardiovascular disease becomes more prevalent, supporting strong growth prospects for digital healthcare services that combine wearable devices with AI-powered analysis.
The FDA clearance is also expected to support Seers’ broader global expansion beyond the U.S. market. Because the FDA is regarded as one of the world’s most credible medical device regulatory authorities, the approval is expected to serve as an important reference in future regulatory approvals and business negotiations in overseas markets, including the Middle East and Asia. Following a recent supply agreement in the United Arab Emirates, the company expects the FDA clearance to further accelerate its international business expansion.
After demonstrating commercial success in Korea’s hospital market through its AI medical platform, thynC™, Seers plans to make the United States and the Middle East its two primary global growth engines with mobiCARE. Leveraging clinical data, AI analytics technology and hospital operating experience accumulated in Korea, the company aims to become a global AI healthcare platform provider focused on the U.S. Medicare market and countries in the Gulf Cooperation Council (GCC).
“This FDA clearance provides the foundation to validate in the U.S. market the AI-powered ECG analysis platform that has already demonstrated its commercial value in Korea,” CEO Lee Young-shin said. “We will move ahead with outpatient validation and entry into the Medicare market as planned and use that as the foundation for a phased expansion of our global business.”
The company’s name, Seers, reflects the meaning of “pioneer.” It embodies the founding philosophy of anticipating changes in healthcare and building a new medical system before digital healthcare became commercially established.
